T Cell ELISPOT Testing
Leaders in T cell ELISPOT Assays and Testing
As pioneers and leaders in cellular immune monitoring (CMI), one of our greatest strengths lies in high-throughput T cell monitoring capabilities and world-class ELISPOT (Enzyme-Linked ImmunoSpot® Assay) expertise.
With decades of experience performing contract research, many pharmaceutical and biotechnology companies have entrusted us with evaluating test subject responses to their vaccines, drugs, and biological products using our ImmunoSpot® technique.
Interferon (IFN)-gamma T cell assays
The ability to measure T cell antigen response is vital for basic research, drug discovery, and management of a range of important diseases. ELISPOT testing is particularly useful in areas when it is necessary to measure low-frequency T cell responses for the ex vivo readout of immune responses.
Having single-cell resolution T cell readouts is critical for better understanding and treatment of allergies and autoimmunity, predicting rejection/acceptance responses in organ transplantation, improving drug and vaccine development, monitoring various cancer treatments, and more.
The ELISPOT/ImmunoSpot® technique generates single-cell, secretory footprints in the form of colored spots within a 96-well plate. These images can then be scanned, counted, and readily evaluated for statistical significance using our ImmunoSpot® analyzers.
The method can determine whether a patient/sample population responds positively or negatively to a vaccine, drug, or biological product and, in addition, measure the extent of each person’s immune response. It opens the door for other means of data evaluation, such as:
- Testing T cell-mediated immunity at a single-cell level for pre-clinical and clinical specimens
- Determinant mapping with overlapping peptides
- Measurement of cytotoxic T cell responses
- The ability to run multiple assays using a limited number of cells/specimens
- High-throughput testing capacity (~150 specimens per day, ~450 specimens per week)